Počet záznamov: 1
axitinib
SYS d000077784 LBL 00000nz--a2200181n--4500 005 20250606222656.5 008 190101|||anznnbabn-----------|-a|a------ 040 $b slo $a BA006 $d BA006 065 $a D02.065.277.051 065 $a D02.241.223.100.100.115 065 $a D02.455.426.559.389.127.085.093 065 $a D03.383.129.539.487.065 065 $a D03.633.100.449.065 066 $a 01 $c 03 150 $a axitinib $x AA $x AD $x AE $x AG $x AI $x AN $x BL $x CF $x CH $x CL $x CS $x EC $x HI $x IM $x IP $x ME $x PD $x PK $x PO $x RE $x SD $x ST $x TO $x TU $x UR $2 slo 450 $w v $a AG 013736 $2 slo 450 $w v $a Inlyta $2 slo 550 $7 sllk_us_auth*d000970 $Y Antineoplastic Agents $w P $a antineoplastiká 550 $7 sllk_us_auth*d047428 $Y Protein Kinase Inhibitors $w P $a inhibítory proteínkináz 665 $a 2019 (2005) $2 eng 680 9-
$i A benzamide and indazole derivative that acts as a TYROSINE KINASE inhibitor of the VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR. It is used in the treatment of advanced RENAL CELL CARCINOMA. $2 eng 750 -2
$a Axitinib $2 eng 980 $x M
Počet záznamov: 1